Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.